76
|
Darbonne WC, Du X, Dhawan P, Hartley D, Tarrant J, Taylor H, Cain G, Shih LM, Brachmann RK, Phung Q, Weekes CD, LoRusso P, Patnaik A, Xiang H, Ramakrishnan V. Mechanism for platelet reduction in anti-neuropilin-1 (MNRP1685A)–treated phase I patients. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e13598] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
77
|
Patnaik A, Appleman LJ, Mountz JM, Ramanathan RK, Beeram M, Tolcher AW, Papadopoulos KP, Lotze MT, Petro DP, Laymon C, Paige L, Rajagopalan P, Jeffers M, Roth D, Dubowy RL. A first-in-human phase I study of intravenous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: Results of dose-escalation phase. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3035] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
78
|
Shih KC, Infante JR, Papadopoulos KP, Bendell JC, Tolcher AW, Burris HA, Beeram M, Jackson L, Arcos R, Westin EH, Farrington D, McGlothlin A, Hynes S, Leohr J, Brandt JT, Nasir A, Patnaik A. A phase I dose-escalation study of LY2523355, an Eg5 inhibitor, administered either on days 1, 5, and 9; days 1 and 8; or days 1 and 5 with pegfilgrastim (peg) every 21 days (NCT01214642). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.2600] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
79
|
Kurzrock R, Patnaik A, Rosenstein L, Fu S, Papadopoulos KP, Smith DA, Falchook GS, Chambers G, Gauvin JL, Naing A, Smith LS, Gonzalez T, Tsimberidou AM, Mays TA, Cox DS, Hong DS, DeMarini DJ, Le NT, Morris SR, Tolcher AW. Phase I dose-escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3085] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
80
|
Papadopoulos KP, Chau NG, Patnaik A, Adriaens L, Lalani AS, Daly C, Siu LL. A phase I first-in-human study of REGN910, a fully human and selective angiopoietin-2 monoclonal antibody, in patients with advanced solid tumor malignancies. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
81
|
Papadopoulos KP, Mendelson DS, Tolcher AW, Patnaik A, Burris HA, Rasco DW, Bendell JC, Gordon MS, Kato G, Wong H, Bomba D, Lee S, Gillenwater HH, Woo T, Infante JR. A phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3075] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
82
|
Dienstmann R, Tolcher AW, Papadopoulos KP, Rasco DW, Tabernero J, Brana I, Piera A, Skartved NJ, Aladdin H, Petersen J, Patnaik A. Phase I trial of the first-in-class EGFR antibody mixture, Sym004, in patients with advanced solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3089] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
83
|
Schwartzberg LS, Beeram M, Patnaik A, Tolcher AW, Itri L, Olson AL, Seidman AD. Tesetaxel, an advanced-generation oral taxane, as first-line treatment in women with metastatic breast cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
84
|
Biondo A, Yap TA, Yan L, Patnaik A, Fearen I, Baird RD, Papadopoulos KP, Delgado LM, Taylor A, Lupinacci L, Blackman SC, Decordova S, Tall M, Heaton S, Garrett MD, Sullivan D, De Bono JS, Tolcher AW. Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3037] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
85
|
Beryozkina A, Nichols GL, Reckner M, Vassilev LT, Rueger R, Jukofsky L, Middleton S, Andreeff M, Padmanabhan S, Strair R, Delioukina ML, Maslak PG, Hillmen P, Kurzrock R, Gore L, Patnaik A, Maki RG, Schwartz GK, Wagner AJ, Zhi J. Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112, an oral murine double minute 2 (MDM2) antagonist, in patients with leukemias and solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3039] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
86
|
Rasco DW, Patnaik A, Amaravadi RK, Papadopoulos KP, Haas NB, Tolcher AW, Beeram M, Harlacker K, Drouin MA, Tawashi M, Wang J, Karam A, Maroun CR, Bonfils C, Mehran M, Besterman JM, O'Dwyer PJ. Determination of the maximum tolerated dose (MTD) of MGCD265, an oral Met/VEGFR multitargeted receptor tyrosine kinase inhibitor, in combination with docetaxel. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
87
|
Tolcher AW, Bendell JC, Patnaik A, Papadopoulos K, Bellew KM, Cox DS, Xu Y, Burris HA, Le N, Infante JR. A phase Ib study of the MEK inhibitor GSK1120212 combined with gemcitabine in patients with solid tumors: Interim results. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.278] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
278 Background: GSK1120212 (212) is a reversible, allosteric inhibitor of MEK1/MEK2. The objectives of this open-label, single-arm study are to evaluate the safety, pharmacokinetics (PK), and anti-tumor activity of 212 + gemcitabine (gem), and to determine the recommended phase II regimen (RP2R) in patients (pts) with advanced solid tumors. Methods: 212 (1-2.5mg) is given continuously, orally, once daily. Gem (1,000mg/m2) is infused on days 1, 8, and 15 every 28 days. Doses are escalated to the maximum tolerated dose (MTD) and followed by an expansion cohort to confirm the RP2R tolerability. Results: 28 pts received ≥ 1 dose of 212 + gem, including 8 pancreatic, 6 breast, and 4 non-small cell lung (NSCLC) cancer pts. The MTD and RP2R is 2mg 212 + 1,000mg/m2 gem. Dose-limiting toxicities (DLTs) are G3/G4 febrile neutropenia (n=2), G3 AST elevation (n=2), and G2 uveitis (n=1). 16 serious adverse events (SAEs) were reported; 5 were considered to be related to study drugs (1 pneumonitis, 3 febrile neutropenia, 1 dyspnea). All DLTs and SAEs have resolved. The most common AEs at the RP2R (n=18) were rash (78%), fatigue (67%), thrombocytopenia (61%), neutropenia (50%), decreased appetite (50%), nausea (44%), diarrhea and constipation (39%); all ≤ G2 except thrombocytopenia (17% ≥ G3) and neutropenia (33% ≥ G3). Co-administration did not affect the PK profiles of 212 or gem. 25 pts had measurable disease at baseline. 1 pancreatic cancer pt with previous radiotherapy and 2 cycles of gem achieved a partial response and stayed on study for 6 months. 3 additional pancreatic cancer pts reported stable disease; 2 of which were on the study for 3.5-5 months and the third pt continues in the study. 1 triple-negative breast cancer pt, refractory to chemotherapy, and 1 parotid cancer pt experienced a complete response of their target lesions. Conclusions: 212 + gem is tolerable with an acceptable safety profile in this pt population, with evidence of clinical activity in pancreatic cancer. A randomized phase II study in previously untreated patients with metastatic pancreatic cancer is underway to investigate the clinical activity of this combination. [Table: see text]
Collapse
|
88
|
Weekes C, Hedge P, Xin Y, Yu R, Xiang H, Gore L, Beeram M, Brachmann R, Patnaik A. 372 A phase I dose-escalation study of the fully human monoclonal antibody MNRP1685A (anti-NRP1) administered intravenously to patients with advanced solid tumors. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)72079-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
89
|
Tolcher A, Patnaik A, Papadopoulos K, Mays T, Stephan T, Humble D, Frohlich M, Sims R. 376 Preliminary results from a Phase 1 study of D-3263 HCl, a TRPM8 calcium channel agonist, in patients with advanced cancer. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)72083-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
90
|
Patnaik A, Courtney K, Signoretti S, Loda M, Grant A, Pedrosa I, Lunsford E, Frangioni J, Pandolfi P, Cantley L. 27A Targeting the PI3K/mTOR pathway in genetically engineered mouse models of advanced prostate cancer. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)71731-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
91
|
Nieves F, Moore M, Mann M, Moskaluk C, Tolcher A, Papadopoulos K, Patnaik A, Kaufman J, Wick M. 154 Establishment and evaluation of patient-derived tumor models of adenoid cystic carcinoma: Effects of chemotherapeutics and targeted therapies on human ACC xenografts. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)71859-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
92
|
Shimizu T, Tolcher A, LoRusso P, Papadopoulos K, Patnaik A, Smith L, Keegan M. 364 The first-in-human, first-in-class study of CUDC-101, a multi-targeted inhibitor of HDAC, EGFR, and HER2: A Phase I study in patients with advanced cancer. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)72071-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
93
|
Papadopoulos K, Crippa S, Hanssen A, Montagnoli A, Fiorentini F, Tolcher A, Martignoni M, Isacchi A, Laffranchi B, Patnaik A. 385 A first in human phase 1 study of the safety and pharmacokinetics of a novel Cdc7 inhibitor NMS-1116354, administered orally to patients with solid tumors. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)72092-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
94
|
O'Dwyer P, Papadopoulos K, Amaravadi R, Harlacker K, Beeram M, Drouin M, Mehran M, Besterman J, Maroun C, Patnaik A. 396 MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor, in combination with docetaxel: clinical and preclinical experience. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)72103-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
95
|
Patnaik A, Besterman J, Tolcher A, Mehran M, Drouin M, Maroun C, Bonfils C, Beeram M, Martell R, Papadopoulos K. 395 MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor, in combination with erlotinib: clinical and preclinical experience. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)72102-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
96
|
Beeram M, Papadopoulos K, Patnaik A, Qureshi A, Tolcher AW. Phase I dose-ranging, pharmacokinetic (PK) study of tesetaxel, a novel orally active tubulin-binding agent. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e13075] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
97
|
Patnaik A, Weekes CD, Hegde P, Xin Y, Yu R, Xiang H, Brachmann RK, LoRusso P. A phase Ib study to evaluate the fully human monoclonal antibody MNRP1685A (anti-NRP1) administered intravenously in combination with bevacizumab with or without weekly paclitaxel in patients with advanced solid tumors. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.tps180] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
98
|
Brana I, LoRusso P, Baselga J, Heath EI, Patnaik A, Gendreau S, Laird A, Papadopoulos K. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3030] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
99
|
Thompson DS, Patnaik A, Bendell JC, Papadopoulos K, Infante JR, Mastico RA, Johnson D, Qin A, O'Leary JJ, Tolcher AW. A phase I dose-escalation study of IMGN388 in patients with solid tumors. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3058] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
100
|
Lee P, Wong AF, Burris HA, Papadopoulos K, Sausville EA, Rosen PJ, Mendelson DS, Infante JR, Patnaik A, Gordon MS. Updated results of a phase Ib/II study of carfilzomib (CFZ) in patients (pts) with relapsed malignancies. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.8147] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|